Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 31

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 31
---
spectus is accurate as of any date other than the date of such incorporated document. The mailing of this proxy statement/prospectus to our shareholders will not create any implication to the contrary. This proxy statement/prospectus does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, or the solicitation of a proxy, in any jurisdiction in which or from any person to whom it is unlawful to make any such offer or solicitation in such jurisdiction. When used in this proxy statement/prospectus, all references to the “NLS,” refer to NLS Pharmaceutics Ltd.; all references to “Merger Sub” refer to NLS Pharmaceutics (Israel) Ltd., an Israeli company and a wholly owned subsidiary of NLS, formed for the purpose of effecting the Merger as described in this proxy statement/prospectus; all references to “Kadimastem” refer to and Kadimastem Ltd., an Israeli publicly traded company limited by shares (TASE: KDST); all references to “combined company” refer to the combined company immediately following completion of the Merger and the other transactions contemplated by the Merger Agreement; all references to “Common Share,” or “NLS Common Share” refer to a common share of NLS, 0.03 CHF nominal value per share, subject to changes pursuant to the NLS Meeting; all references to “Preferred Shares” or “NLS Preferred Shares” refer to the preferred shares of NLS, CHF 0.03 nominal value per share; all references to “Preferred Participation Certificates” or “NLS Preferred Participation Certificates” refer to the preferred participation certificates of NLS, CHF 0.03 nominal value per share; all references to “NLS Board” refer to the board of directors of NLS; and all references to “Kadimastem Board” refer to the board of directors of Kadimastem. All information included herein relating to NLS Common Shares or price per share of NLS reflects the 1 -for-40reverse split effected by NLS on September27, 2024. Further, on January14, 2025, the shareholders of NLS approved a change in the par value of the NLS Common Shares from CHF 0.80 to CHF 0.03 per share, effective January17, 2025.
TABLE OF CONTENTS

|                                                                                                                             |     | Page |
| QUESTIONS AND ANSWERS